Stocks and Investing
Stocks and Investing
Thu, September 29, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, September 28, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mohit Bansal Maintained (BIIB) at Buy with Increased Target to $350 on, Sep 28th, 2022
Mohit Bansal of Wells Fargo, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $265 to $350 on, Sep 28th, 2022.
Mohit has made no other calls on BIIB in the last 4 months.
There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 2 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Paul Matteis of "Stifel" Maintained at Hold with Decreased Target to $223 on, Monday, September 12th, 2022
- Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $200 on, Thursday, July 21st, 2022
These are the ratings of the 4 analyists that currently disagree with Mohit
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $265 on, Thursday, September 22nd, 2022
- Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $270 on, Thursday, July 21st, 2022
- Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $250 on, Thursday, July 21st, 2022
- Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $230 on, Monday, July 18th, 2022
Contributing Sources